Transgene SA
TNG
Company Profile
Business description
Transgene SA is a biotechnology company that designs and develops virus based immunotherapy products focused on the development of individualized therapeutic vaccines against cancers. The flagship program, TG4050, is an individualized therapeutic vaccine based on the myvac platform. The company also has other viral vector-based programs, including BT-001, an oncolytic virus based on the Invir.IO viral backbone, which is in clinical development. In addition, it conducts discovery and preclinical work, aimed at developing novel immunotherapies.
Contact
400, Boulevard Gonthier d’Andernach
Parc d’Innovation
Illkirch-Graffenstaden
Strasbourg67400
FRAT: +33 388279100
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
155
Stocks News & Analysis
stocks
Why stocks sometimes fall for no obvious reason
How the private markets impact all equity investors.
stocks
Poor organic growth obscured by acquisition for ASX listed share
Sales dropped by 2% without impact of acquisition.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,877.20 | 15.00 | -0.17% |
| CAC 40 | 8,116.94 | 30.94 | 0.38% |
| DAX 40 | 24,856.79 | 250.02 | 1.02% |
| Dow JONES (US) | 50,613.10 | 327.44 | 0.65% |
| FTSE 100 | 10,461.22 | 17.75 | 0.17% |
| HKSE | 25,606.03 | 219.51 | 0.86% |
| NASDAQ | 26,396.38 | 103.29 | 0.39% |
| Nikkei 225 | 63,339.07 | 1,654.93 | 2.68% |
| NZX 50 Index | 12,991.31 | 113.24 | 0.88% |
| S&P 500 | 7,478.42 | 32.70 | 0.44% |
| S&P/ASX 200 | 8,657.00 | 15.10 | -0.17% |
| SSE Composite Index | 4,112.90 | 35.62 | 0.87% |